BEIGENE'S INTERNAL PIPELINE

THREE LATE-STAGE, AND EIGHT EARLY-STAGE CLINICAL ASSETS

BeiGene

Global

China



*Some indications will not require a non-pivotal Ph2 clinical trial prior to beginning pivotal Ph2 or Ph3 clinical trials. **Confirmatory clinical trials post approval are required for accelerated approvals. † R/R or not suitable for chemo-immunotherapy; ^R/M: Recurrent / Meta static

BEIGENE'S COLLABORATIVE PIPELINE

BeiGene

China Global

COMPOUND	(TARGET) / PROGRAM	DOSE ESC.	DOSE EXPANSION		PIVOTAL		COMMERCIAL RIGHTS	PARTNER
		PH1a	PH1b	PH2*	PH2**	PH3		
sotorasib	(KRAS G12C)	Solid Tumors, NSCLC, CRC						
ravurutamab^^	(BCMA)	MM						
AMG 176	(Mcl-1, SM (i.v.))	Hematologic malignancies						
AMG 330^	(CD33)	Myeloid malignancies						
AMG 673^^	(CD33)	AML						
AMG 427^^	(FLT3)	AML						
tarlatamab^^	(DLL3)	SCLC						
acapatamab^^	(PSMA)	Prostate cancer					China	Amgen
AMG 509^	(STEAP1 XmAb)	Prostate cancer						
AMG 199^^	(MUC17)	GC/GEJC						
AMG 910^^	(Anti-CLDN18.2)	GC/GEJC						
AMG 650	(oral small molecule)	Solid tumors						
AMG 506	(FAP x 4-1BB, DARPin®)	Solid tumors						
AMG 994		Solid tumors						
AMG 397	(MCL-1)	Myeloid malignancies						
AMG 256	(Anti-PD-1 x IL21 mutein)	Solid tumors						
sitravatinib†	(multi-kinase inhibitor) + tislelizumab	NSCLC, RCC, OC, MEL					Asia ex-Japan, AU, NZ	Mirati
	Mono, + tislelizumab	HCC, GC/GEJC						
zanidatamab††	(HER2, bispecific antibody)	Breast cancer, GEA					Asia ex-Japan, AU, NZ	Zymeworks
		Biliary tract cancers						
ZW49	(HER2, bispecific ADC)	HER2-expressing cancers					Asia ex-Japan, AU, NZ	Zymeworks
BGB-3245[1]	(B-RAF)	Solid tumors					Asia ex-Japan	SpringWorks[1]
BA3017	(CTLA4) Mono, + tislelizumab	Tech transfer in progress					Global	BioAtla
SEA-CD70	(anti-CD70)	MDS, AML					Asia ex-Japan, AU, NZ	Seagen
DKN-01	(DKK1) + tislelizumab ± chemo	GC/GEJC					Asia ex-Japan, AU,NZ	Leap Therapeutics
ABI-H0731	(HBV core inhibitor)	Chronic Hepatitis B Virus						
ABI-H2158	(HBV core inhibitor)	Chronic Hepatitis B Virus					China	Assembly Bio
ABI-H3733	(HBV core inhibitor)	Chronic Hepatitis B Virus						

* Some indications will not require a non-pivotal Ph2 clinical trial prior to beginning pivotal Ph2 or Ph3 clinical trials. **Confirmatory clinical trials post approval are required for accelerated or conditional approvals. ^ BiTE, ^^ HLE BiTE, † Mirati is also conducting its own clinical studies with sitravatinib, including the Phase 3 SAPPHIRE trial in non-Sq NSCLC. †† ZW25, AML: acute myeloid leukemia, HLE BiTE: Half-life extended Bi-specific T-cell engagers, GC/GEJ: gastric cancer/gastroesophageal junction, HCC: hepatocellular carcinoma, IND: Investigational New Drug, MEL: melanoma, MM: multiple myeloma, NHL: non-Hodgkin's lymphoma, N/SCLC: non-/small cell lung cancer, OC: ovarian cancer, RCC: renal cell carcinoma, SM: small molecule; 1. By MapKure, a JV with SpringWorks